RGCC cancer analysis, mutational burden and instability sequencing (CAMBISeq) provides next- generation sequencing analysis on both DNA and RNA. RGCC CAMBISeq can help to identify variants in more than 500 genes, help detect fusions, and calculate tumour mutational burden (TMB) and microsatellite instability (MSI). TMB refers to the number of mutations within coding region, are used as biomarker of sensitivity to immunotherapy. Highly mutated tumours usually obtain neoantigens which make them targets of activated immune cells. TMB can be accurately measured in a specific panel of genes, helping to avoid the expensive and time-consuming technique of whole exome sequencing.